SCHEMBL26481973

SCHEMBL26481973

CC(=O)OCC1OC(OCCCCC(=O)OCc2ccccc2)C(C)C(C)C1OC(C)=O

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.48
KMT2A Q03164 1/20 0.48
TSHR P16473 2/20 0.46
ALDH1A1 P00352 4/20 0.45
CYP2D6 P10635 4/20 0.45
MAPK1 P28482 1/20 0.45
POLB P06746 1/20 0.43
LGALS8 O00214 1/20 0.39
MAPT P10636 3/20 0.39
CYP3A4 P08684 3/20 0.39
CYP2C19 P33261 3/20 0.39
PAX8 Q06710 1/20 0.39
CYP2C9 P11712 2/20 0.38
P4HB P07237 1/20 0.38
PDIA4 P13667 1/20 0.38
PDIA3 P30101 1/20 0.38
TNF P01375 1/20 0.38
THRB P10828 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27416860 0.99 LMNA (0.48) LMNAKMT2ATSHRALDH1A1CYP2D6
SCHEMBL27416853 0.97 LMNA (0.49) LMNAKMT2ATSHRALDH1A1CYP2D6
SCHEMBL27416867 0.93 LMNA (0.51) LMNAKMT2ATSHRALDH1A1CYP2D6
SCHEMBL22697508 0.90 CYP2D6 (0.53) LMNAKMT2ATSHRALDH1A1CYP2D6
SCHEMBL26350712 0.90 CYP2D6 (0.53) LMNAKMT2ATSHRALDH1A1CYP2D6
SCHEMBL9604424 0.90 ALDH1A1 (0.42) LMNAKMT2ATSHRALDH1A1CYP2D6
SCHEMBL16248647 0.90 ALDH1A1 (0.42) LMNAKMT2ATSHRALDH1A1CYP2D6
SCHEMBL27416844 0.90 LMNA (0.48) LMNAKMT2ATSHRALDH1A1CYP2D6
SCHEMBL18073843 0.89 LMNA (0.57) LMNAKMT2ATSHRALDH1A1CYP2D6
SCHEMBL17589419 0.89 ALDH1A1 (0.41) LMNAKMT2ATSHRALDH1A1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240218023-A1 CYCLIC PEPTIDE-N-ACETYLGALACTOSAMINE (GALNAC) CONJUGATES FOR DRUG DELIVERY TO LIVER CELLS MICROBIO (SHANGHAI) CO., LTD. (CN) 2024-07-04 US disclosed
US-20230139322-A1 SiRNA molecule inhibiting the expression of the PCSK9 gene and use thereof ARGORNA PHARMACEUTICALS LIMITED (CN) 2023-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230139322-A1 SiRNA molecule inhibiting the expression of the PCSK9 gene and use thereof PCSK9, PCSK7, PCSK6 LMNA 400/4885KMT2A 1244/4885TSHR 4233/4885
US-20240218023-A1 CYCLIC PEPTIDE-N-ACETYLGALACTOSAMINE (GALNAC) CONJUGATES FOR DRUG DELIVERY TO LIVER CELLS GALNT1, CSGALNACT1, GALNT2 LMNA 1541/4885KMT2A 3597/4885TSHR 1210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.